1 / 25

Antidepressant Classes

Antidepressant Classes. Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline (Zoloft) Fluoxetine (Prozac) Paroxetine (Paxil) Citalopram (Celexa) Escitalopram (Lexapro) Tricyclic Antidepressant (TCA) Amitriptyline (Elavil) Nortriptyline (Pamelor) Imipramine (Tofranil)

Ava
Télécharger la présentation

Antidepressant Classes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antidepressant Classes • Selective Serotonin Reuptake Inhibitor (SSRI) • Sertraline (Zoloft) • Fluoxetine (Prozac) • Paroxetine (Paxil) • Citalopram (Celexa) • Escitalopram (Lexapro) • Tricyclic Antidepressant (TCA) • Amitriptyline (Elavil) • Nortriptyline (Pamelor) • Imipramine (Tofranil) • Desipramine (Norpramin) • Doxepine (Sinequan) • Trimipramine (Surmontil) • Protriptyline (Vivactil) • Maprotiline (Ludiomil) • Amoxapine (Ascendin) • Clomipramine (Anafranil)

  2. Antidepressant Classes • Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) • Venlafexine (Effexor) • Desvenlafaxin (Pristiq) • Duloxetine (Cymbalta) • MAO Inhibitors • Phenelzine (Nardil) • Tranylcypromine (Parnate) • Atypical Antidepressants • Bupropion (Wellbutrin) • Trazodone (Desyrel) • Mirtazepine (Remeron)

  3. Antidepressant Therapy: Treatment Decisions Risk of treatment vs. no treatment of depression • No treatment • Self-medication (alcohol, tobacco, other drugs) • Impaired judgment  poor or noncompliance with prenatal care • Poor appetite  poor nutrition • Anxiety • Insomnia • Disruption in family relationships: • Impaired maternal-infant (or other children) bond  psychosocial problems • Impaired relationship with partner  paternal depression

  4. Antidepressant Therapy: Treatment Decisions Risk of treatment vs. no treatmentof depression • No treatment • Postpartum depression • Suicide • Not fully characterized/not conclusive: preterm birth, low birth weight, miscarriage, hyperemesis gravidarum • Treatment • Side effects of medication • Teratogenicity • Neurobehavioral syndrome

  5. Antidepressant Therapy • Teratogenicity • Background risk to fetus (general population) of minor or major malformation ≈ 2 to 4 % • Overall, antidepressants appear safe in pregnancy Caveats: • many drugs are relatively new – insufficient data exists • we cannot ethically subject pregnant women to randomized controlled trials to determine drug safety – we are limited to observation studies • distinguishing problems due to medication from the small but significant background rate of congenital anomalies is difficult

  6. Antidepressant Therapy Teratogenicity • TCAs Since they have been in use for a relatively long time, are considered to have the lowest known risk in pregnancy (and breastfeeding) • TCAs are much more dangerous if overdosed • SSRIs • Paroxetine (Paxil) – 1st trimester  atrial and ventricular septal defects + right ventricular outflow defects • Sertraline (Zoloft) – atrial and ventricular septal defects + oomphalocele • Citalopram (Celexa) + Esitalopram (Lexapro) – anencephaly, omphalocele, craniosynostosis

  7. Antidepressant Therapy • SSRIs and TCAs – late pregnancy  persistent pulmonary hypertension • Fluoxetine (Prozac) – best studied SSRI (safety/efficacy in pregnancy and lactation) but has a long half life + high rate of transfer to neonate through breastfeeding • Miscarriage/stillbirth/low birth weight – data is conflicting and inconclusive

  8. Antidepressant Therapy Summary • Defects are rare – absolute risk is very small – probably not enough to warrant a switch or discontinuation • May be enough data to not pick as first line drug in pregnancy (or planning pregnancy): • Paroxetine (Paxil) • Fluoxetine (Prozac) – if will be breastfeeding • Larger prospective studies with better controls for confounding variables are required

  9. Antidepressants in Pregnancy • Neonatal Behavioral Syndrome • SSRI “class effect – late use (after 24 weeks) in pregnancy • Withdrawal vs. serotonin toxicity syndrome? • Absolute risk – up to 30 % of exposed neonates • Symptoms may arise immediately after birth and resolve within 2 weeks • Most reports have involved Fluoxetine (Prozac) and Paroxetine (Paxil)

  10. Antidepressants in Pregnancy • Neonatal Behavioral Syndrome • Jitteriness/tremor • Irritability/constant crying • Mild respiratory distress/tachypnea • Hypoglycemia • Poor tone • Weak cry • Desaturation on feeding • Temperature instability

  11. SSRI/SNRI Discontinuation Syndrome in Adults F.I.N.I.S.H. • Flu-like symptoms:fatigue, muscle aches, headache, diarrhea • Insomnia:vivid or disturbing dreams • Nausea • Imbalance:gait instability, dizziness, lightheadedness, vertigo • Sensory disturbance: paresthesia, “electric shock” sensation, visual disturbance • Hyperarousal: anxiety, agitation • Onset:24-72 hours+Resolution:1-14 days • Incidence:~ 20 - 40 %(who have been treated at least 6 weeks)

  12. SSRI/SNRI Toxicity in Adults • CNS & Neuromuscular:tremor, restlessness, agitation, insomnia, dystonia, hypertonia, dyskinesia, paresthesia, convulsion, congnitive impairment • GI:nausea, vomiting, diarrhea • Autonomic instability:respiratory distress, tachypnea, hyperthermia, temperature instability, chills, rigors, diaphoresis, tachycardia • Onset: variable • Resolution: hours to several days

  13. Antidepressant use during breastfeeding • Less data re: long-term neurodevelopmental consequences of neonatal exposure (vs. in utero exposure) • Few isolated cases of adverse effects reported • In general: a) risk of not breastfeeding > risk of antidepressants; b) placental passage of antidepressant > breast milk – makes sense to continue medication started during pregnancy • General recommendations: • Take antidepressant immediately after breastfeeding to minimize exposure to peak drug concentrations • Monitor for effects on infant: sedation, irritability, change in feeding • Sertraline (Zoloft) and Paroxetine (Paxil) appear safest • Fluoxetine (Prozac) – avoid due to long T ½ (safer after 4 months )

  14. Antidepressant Treatment Principles • Begin with a modest dose • For partial response or nonresponse: • Optimize dose or duration of therapy • Minimum of six (6) weeks. If a patient exhibits a significant partial response during this initial period, another 4-6 weeks of treatment should be added (Total: 10-12 weeks) • Some may benefit from antidepressant dosages that are higher than recommendations • Drug Substitution • If no (or inadequate) response – switch to another antidepressant class • Exception: SSRI • Combination Therapy – add another antidepressant (another class)

  15. Antidepressant Treatment Principles Partial response and Nonresponse • Augmentation – add a second agent (not an antidepressant) • Lithium • Thyroid hormone (Cytomel) • Pindolol (Viskin) • Buspirone (BuSpar) • Electoconvulsive Therapy • For psychotic depression and severe refractory depression

  16. Antidepressant Treatment Principles: Follow-up • Every 1-2 weeks for six to eight weeks during the initiation phase of medication treatment – office visits for supportive care, access to provider by phone, and/or proactive phone calls to check on therapeutic response, side effects, and adherence to treatment • First episode of depression – medication for at least 6-9 months after remission • Two or more episodes of depression – two years (or more) of medication • Taper medication over 2-4 weeks to avoid withdrawal

  17. STAR-D trial • Sequenced Treatment Alternatives to Relieve Depression • Funded by National Institute of Mental Health and published 11/2006 • The largest and longest study to evaluate depression treatment • Overall objective: define preferred treatments for depression – in a way that mirror methods that clinicians use in practice: • Determine best “next-step” treatments for depressions not responding satisfactorily to one or more prior treatment attempts • Compare relative efficacy of different treatment approaches • Participants: • 18-75 years old (64 % female) • Met DSM-IV criteria for Major Depressive Disorder • Not pregnant or breastfeeding • 4,041 enrolled at 41 clinical sites (18 primary care + 23 psychiatric care)

  18. STAR-D trial • All patients were treated for 12 weeks at each level • All patients who achieved remission of depression could enter a 12-month follow-up phase (continue with effective medication + any psychotherapy, medication, or medication dosage change could be made) • All patients who did not achieve remission (or were unable to tolerate their medication) were strongly encouraged to proceed to the next treatment phase (level)

  19. STAR-D trial Level I 4,041 enrolled 3671 1425 remission Follow-up Citalopram (Celexa) Exit (766) 1430 To Level II (no remission)

  20. STAR-D trial Level II • Participants were asked: • Would it be equally acceptable to receive “switch” or “augmentation”? (21/1430) • Would you accept only one or the other approaches? (1409/1430) From Level I Switch option randomized Augment option 1430 238 239 250 62 279 286 85 Cognitive Behavioral Therapy Cognitive Behavioral Therapy Sertraline Bupropion-SR Venlafaxine-XR Bupropion-SR Buspirone (Wellbutrin) (BuSpar) (Zoloft) (Wellbutrin) (Effexor) + citalopram + citalopram + citalopram • Switch Option: • more severely ill + more side effects (citalopram) • side effects, efficacy, time to remission, drop out rates were the same

  21. STAR-D trial Level II From Level I randomized 1430 238 239 250 62 279 286 85 Cognitive Behavioral Therapy Cognitive Behavioral Therapy Sertraline Bupropion-SR Venlafaxine-XR Bupropion-SR Buspirone (Wellbutrin) (BuSpar) (Zoloft) (Wellbutrin) (Effexor) + citalopram + citalopram + citalopram Exit (389) Follow-up (544) Exit (38) Follow-up (78) To Level III (359) To Level II A (31)

  22. STAR-D trial For participants (31) who received cognitive therapy alone or cognitive therapy plus citalopram at Level II and either did not receive remission or were unable to tolerate Level II A * This step was included to ensure that all participants who entered Level III had received at least two medication trials 15 16 Bupropion-SR Venlafaxine-XR (Wellbutrin) (Effexor) Exit (5) Follow-up (8) To level III (18)

  23. STAR-D trial • Augmentation: • Lithium and T3 equally effective • 23 % stopped Lithium due to side effects (vs. 10 % with T3) From Level 2 A (18) Level III From Level 2 (359) randomized • Switch: • No difference between Remeron and Pamelor 377 121 114 69 73 Mirtazapine (Remeron) Nortriptyline (Pamelor) Lithium + Level 2 treatment T3 + Level 2 treatment Switch Exit (169) Follow-up (99) To level IV (109) Augment

  24. STAR-D trial From Level 3 Level IV randomized (109) Switch Tranylcypromine (Parnate) Venlafaxine XR (Effexor XR) + Mirtazapine (Remeron) * Effexor/Remeron was significantly better tolerated ~ 10 % achieved remission

  25. STAR-D trial Cumulative Remission Rates Level I 100 37 % 37 (Celexa) Theoretical cumulative remission rate: Level II 63 37 + 19 + 6 + 5 = 67/100 31 % (Zoloft, Wellbutrin SR, Effexor XR, BuSar, Cognitive Behavioral Therapy) 19 Level III 44 14 % (Remeron, Pamelor, Lithium, T3) 6 Level IV 38 13 % (Parnate, Effexor XR, Remeron) 5

More Related